

# Elisa Frisaldi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4207158/publications.pdf>

Version: 2024-02-01

29  
papers

704  
citations

623734

14  
h-index

580821

25  
g-index

30  
all docs

30  
docs citations

30  
times ranked

861  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thirty Years of Neuroscientific Investigation of Placebo and Nocebo: The Interesting, the Good, and the Bad. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 323-340.	9.4	21
2	Placebo Effect. , 2022, , 731-738.		0
3	The subthalamic nucleus and the placebo effect in Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 180, 433-444.	1.8	4
4	Effectiveness of a dance-physiotherapy combined intervention in Parkinson's disease: a randomized controlled pilot trial. <i>Neurological Sciences</i> , 2021, 42, 5045-5053.	1.9	16
5	What is the role of placebo in neurotherapeutics?. <i>Expert Review of Neurotherapeutics</i> , 2021, , .	2.8	1
6	Nocebo and the contribution of psychosocial factors to the generation of pain. <i>Journal of Neural Transmission</i> , 2020, 127, 687-696.	2.8	26
7	Placebo and nocebo responses in Parkinson's disease. , 2020, , 527-541.		1
8	Verbal communication about drug dosage balances drug reduction in Parkinson's disease: Behavioral and electrophysiological evidences. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 184-189.	2.2	6
9	The need to investigate nocebo effects in more detail. <i>World Psychiatry</i> , 2019, 18, 227-228.	10.4	3
10	The placebo response in myasthenia gravis assessed by quantitative myasthenia gravis score: A meta-analysis. <i>Muscle and Nerve</i> , 2019, 59, 671-678.	2.2	7
11	Placebo responders and nonresponders: what's new?. <i>Pain Management</i> , 2018, 8, 405-408.	1.5	9
12	How do placebos work?. <i>HÅrre Utbildning</i> , 2018, 9, 1533370.	3.0	17
13	Placebo effects: the need for a new perspective and conceptualization. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 543-544.	3.1	1
14	Placebo response in pain, fatigue, and performance: Possible implications for neuromuscular disorders. <i>Muscle and Nerve</i> , 2017, 56, 358-367.	2.2	32
15	Why We should Assess Patients' Expectations in Clinical Trials. <i>Pain and Therapy</i> , 2017, 6, 107-110.	3.2	47
16	The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning. <i>Movement Disorders</i> , 2017, 32, 1474-1478.	3.9	27
17	Teaching neurons to respond to placebos. <i>Journal of Physiology</i> , 2016, 594, 5647-5660.	2.9	60
18	Role of explicit verbal information in conditioned analgesia. <i>European Journal of Pain</i> , 2015, 19, 546-553.	2.8	42

#	ARTICLE	IF	CITATIONS
19	Placebo and Nocebo Effects: A Complex Interplay Between Psychological Factors and Neurochemical Networks. <i>American Journal of Clinical Hypnosis</i> , 2015, 57, 267-284.	0.6	60
20	Creating placebo responders and nonresponders in the laboratory: boons and banes. <i>Pain Management</i> , 2014, 4, 165-167.	1.5	14
21	The Effects of Placebos and Nocebos on Physical Performance. <i>Handbook of Experimental Pharmacology</i> , 2014, 225, 149-157.	1.8	18
22	Nonlinear analysis of electroencephalogram in frontotemporal lobar degeneration. <i>NeuroReport</i> , 2014, 25, 496-500.	1.2	6
23	Pain and the context. <i>Nature Reviews Rheumatology</i> , 2014, 10, 348-355.	8.0	92
24	Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients. <i>Cortex</i> , 2014, 60, 3-9.	2.4	32
25	Neurochemistry of Placebo Analgesia. , 2013, , 9-14.		2
26	Prognostic Values of Soluble CD30 and CD30 Gene Polymorphisms in Heart Transplantation. <i>Transplantation</i> , 2006, 81, 1153-1156.	1.0	14
27	Identification of a new allele, HLA-DRB5*0113, through three different molecular biology techniques+. <i>Tissue Antigens</i> , 2006, 67, 427-429.	1.0	3
28	Identification of a new HLA-DRB1 allele in three members of an Italian family. <i>Tissue Antigens</i> , 2004, 64, 210-212.	1.0	4
29	CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. <i>Blood</i> , 2003, 101, 1962-1969.	1.4	139